However, the importance of these proliferation rates in our analysis suggests other cytokines could be co-administered with T cell therapy including IL-7, IL-15, or IL-21 to facilitate the production of Tscm and Tcm cells, as these cells may offer greater persistence and therefore more robust anti-tumor activities in vivo across time22,32–40. This evidence concerns the gene IL21 and neoplasm.